Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma in Moderate-Severe COVID-19
NCT04365439Unknown
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Open-label trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19). Primary endpoints: Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors and Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma at 21 days. Status: unknown.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04365439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365439.